#SequentScientific Q3 FY22 concall highlights 🐩🐕‍🦺

Like & Retweet for better reach !

Watch the video to understand the business details :


1. Revenues for the quarter stood at ₹358 Cr (4.8% growth YoY).
2. Growth was mainly driven by the Formulations business which grew at 18.5% YoY on a constant currency basis whereas the API business declined by 20% YoY driven by logistic challenges and subdued demand for Albendazole.
3. Growth in the API portfolio excluding Albendazole has been strong in the first 9 months. Albendazole demand still remains subdued but there is a strong recovery in demand QoQ.
4. There was a significant improvement in the API order book during the quarter although congestion at ports led to 15% of API dispatches not making it to reported numbers. API sales are almost at Q3 FY21 levels which was their best ever quarter in terms of API sales.
5. Growth outlook in the API business for FY23 looks strong as there is going to be a strong recovery in Albendazole and the commercialization of the multi-year supply agreement with a Top 10 animal health company.
6. Strong performance in India, Latam and Turkey were the main drivers in the growth of the formulations business.
7. Turkey business grew at 34% on a constant currency basis although they faced a lot of volatility in terms of the currency. They continue to build Turkey as a major hub for the export business.
The Formulation business has been plagued with rising input prices.
8. Although the price of raw materials is still high, there is a stabilization around the volatility. They have taken some price increases to protect the margins - the major impact of this will come in Q4.
9. The acquisition of Nourrie in Brazil has helped them enter the fast growing companion animals segment. They also acquired the minority interest in Alivira Brazil during the quarter, making it a wholly owned subsidiary.
They now have 100% ownership of all subsidiaries except 40% in Spain and a very negligible share in Sweden.
10. About 1/3rd of revenues from the API business come from Albendazole. WHO is the main buyer for this product and they are currently not buying because schools in Africa are closed. The schools in Africa are opening up and the WHO demand is coming back.
11. The first supplies against the multi-year agreement with a Top 10 Animal Health company are going to happen towards the end of Q1 FY23 or early Q2 FY23. They will not hit the peak revenues from that contract in FY23, the peak will be hit in FY24.
12. Turkey is a very important market to them as it is one of the Top 10 AH markets globally and it is also a very important exporter for the region. It is an injectable based business with good margins and a EU approved facility.
13. The cost of manufacturing in Turkey today is significantly lower than India. The Turkey facility is a comprehensive facility across 8 manufacturing formats including injectables, orals and liquids.
Products manufactured in Turkey are going to be exported to all markets excluding the US.

14. The Brazil business has posted good growth consistently without many fluctuations. They had bought the company when it was bankrupt and it has become one of their best performers.
15. The Bremer (Germany) facility has been delayed due to COVID. It has been delayed for 18 months, it is expected to start this year and it will be ready for USFDA inspection by the end of the calendar year.
16. The Capex over the next 2 years is a little over ₹100 Cr. It will be split between Brazil, Turkey, India and the major part will go towards Germany.

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Value Educator

Value Educator Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @ValueEducator

Feb 19
#Rossaribiotech Q3 2022 Concall Highlights

Like & retweet for better reach !

Operational Highlights

1. Revenues for the quarter stood at ₹428.4Cr, up 104% from same period previous year
2. EBITDA stood at ₹46.7 Cr translating to EBITDA margins of 10.9%

3. PAT stood at ₹22.5 Cr with PAT margins of 5.3%

4. Undertaking price hikes wherever possible to offset these raw material pressures.
5. This is the first full quarter of consolidation of recent acquisitions of Unitop and Tristar in Rossari’s performance. Both these companies delivered growth during the period, which assisted overall performance.
Read 14 tweets
Feb 19
#JBChemicals & Pharmaceuticals Q3 FY22 concall highlights 💊💊

Like & Retweet for better reach !

1. They were the fastest growing company among the Top 30 companies in the domestic formulations market as per IQVIA. JB grew at 27% vs market growth of 18%.
2. Revenues for the quarter stood at ₹601 Cr (10% growth YoY).

3. EBITDA excluding ESOP cost stood at ₹153 Cr (10.5% decline YoY). Gross margins for the quarter stood at 66% although there was significant cost inflation.
4. Cost pressure persists on raw material and packing material, which is expected to continue in the medium-term.

5. During Q3 FY22, Domestic Formulations business launched 12 new products including Molnupiravir, Cilacar TM, Azovas-T and Pirfenidone.
Read 12 tweets
Feb 16
#Kiriindustries Q3 2022 Concall Highlights

Like & Retweet for better reach !

Operational Highlights

1. The revenues for Q3FY22 stood at ₹429.4Cr from ₹310.3 Cr in same period previous year accounting to growth of 38.4% YoY
2. EBITDA for the quarter stood at ₹48.5Cr translating to EBITDA margins of 11.29%

3. The contributors to Consolidated Net Profit after tax of ₹106.02Crore in Q3-FY22 include share of profit of DyStar (associate company of Kiri) to the tune of ₹81.49 Crore, and
₹13.44Crore from Lonsen Kiri Chemical Industries Limited

3. Consolidated Gross Margin has strengthened to 33%, a Q-o-Q increase of 3% which is further expected to improve in coming quarters
Read 12 tweets
Feb 15
#Nazaratechnologies Q3 2022 Concall Highlights 🎱🎲

Financial Update

1. For Q3FY22 revenue was ₹185.8 Cr vs ₹130.4 Cr in Q3FY21 a growth of 42% on YoY basis.

2. Q3 EBITDA was at ₹30.2 Cr as compared to ₹27.3 Cr in the same quarter of the previous year.
3. For 9M FY22 revenue was ₹446.6 Cr vs ₹330.8 Cr in 9MFY21 a growth of 35% on YoY basis.

4. 9MFY22 EBITDA surged by 141% to ₹79.7 Cr as compared to ₹33.1 Cr in 9MFY21.
5. Esports segment recorded revenue of ₹109.3 Cr in Q3FY22 vs ₹57.8 Cr last year in the same quarter, a growth of 89% YoY basis.
Their Gamified early learning segment recorded revenue of ₹47.2Cr.

6. Freemium segment had revenue of ₹5.7 Cr
Read 16 tweets
Feb 15
#Xelpmoc Q3 2022 Concall highlights

Like & Retweet for better reach !

1. Operating revenue for Q3FY22 was ₹18.3 million compared to ₹11.2 in Q2FY22.

2. Net loss for the Quarter was at ₹29.9 million mainly because of Esop.
3. Portfolio value of investments increased from ₹436.3 million on December 31, 2020 to ₹611.2 million on December 31, 2021.
Business Update

1. Signal Analytics, a wholly owned subsidiary raised ₹52.4 million by way of preferential allotment of Pre Series A. Thereby Xelpmoc shareholding in Signal has changed to 91.95% on a fully diluted basis.
Read 11 tweets
Feb 15
#RateGain Q3 ConCall Highlights

Like & Retweet for better reach !

1. RateGain is a company that provides SaaS solutions to Hotels, travel agencies and Car rentals.

Numbers Update-
1. The revenue for the Quarter was up by 57.4% YoY stood at 99 cr
2. The EBITDA stood at 10.6 cr and the margins were 10.7%

3. PAT margins was 6.3%

4. RateGain has gross margins of 80%

- The company repaid a loan of 900 million rupees to Silicon Bank

- Revenue per employee stands at 6.91 million per employee which is up by 17% YoY
- My Hotel Shop contributed 20 cr of revenue in Q3

- 22% of the revenues are from transactions

- 99.9% revenues of the company are recurring
Read 16 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

:(